Nasdaq: Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis Nasdaq: Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older Credit: Getty Images. Xaciato, a lincosamide antibacterial, is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2%. The Food and Drug Administration (FDA) has approved Xaciato™ ...
Business Wire: New Studies Examine Bioavailability and Low Irritancy Potential of a Fixed Combination Clindamycin Phosphate (1.2%) and Low Concentration (2.5%) Benzoyl Peroxide Gel for ... New Studies Examine Bioavailability and Low Irritancy Potential of a Fixed Combination Clindamycin Phosphate (1.2%) and Low Concentration (2.5%) Benzoyl Peroxide Gel for ... Clindamycin (as phosphate) 1%. Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome.
clindamycin phosphate, Clindamycin is predominantly bacteriostatic. Although ... Latest market research report on Global Clindamycin phosphate Topical Market published by Global Market Monitor, offers updated COVID-19 Impacts on global or regional Clindamycin phosphate Topical ...
